Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study

Ilaria Rizzello, Michele Cavo, Luca Dozza, Elena Rivolti, Maria Teresa Petrucci, Valerio De Stefano, Elisabetta Antonioli, Patrizia Tosi, Mattia D’Agostino, Sonia Morè, Alessandro Gozzetti, Michele Cea, Simona Barbato, Paola Tacchetti, Lucia Pantani, Katia Mancuso, Serena Rocchi, Gabriella De Cicco, Alessio Fusco, Elena Zamagni

Research output: Contribution to journalArticlepeer-review

Abstract

Subcutaneous (SC) bortezomib-based regimens represent the standard induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma patients. Published data are based principally on intravenous (IV) administration: this retrospective observational study aimed to define patients’ outcomes upon SC bortezomib administration, before and after ASCT. Of 131 enrolled patients, 86% received bortezomib-dexamethasone plus thalidomide (VTD), 5% plus cyclophosphamide (VCD), and 9% alone (VD), for a median of 4 cycles induction therapy, followed by single (52%) or double (48%) ASCT. 48 patients received consolidation with the same induction regimen. 35% had at least one adverse event, mainly gastrointestinal disorders and peripheral neuropathy (PN). ORR was 93.1%, 97.7% and 100%, after induction, ASCT(s) and consolidation, respectively. Median PFS and PFS2 were 55.8 months and 72 months, respectively, (median follow-up 45.3 months), while median OS was unreached. Concluding, SC bortezomib has similar efficacy with reduced PN than IV administration.

Original languageEnglish
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - 2021

Keywords

  • autologous transplantation
  • multiple myeloma
  • peripheral neuropathy
  • Subcutaneous bortezomib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study'. Together they form a unique fingerprint.

Cite this